Gut mycobiome dysbiosis in inflammatory bowel disease: a systematic review and meta-analysis.

What was studied

This review pooled studies on fungi in the gut in inflammatory bowel disease. It included Crohn's disease and ulcerative colitis. People with these diseases were compared with people without them. The team looked at fungal diversity, which fungi were present, and links to inflammation. The review was not registered ahead of time.

What they found

Crohn's disease was linked to lower fungal diversity than in healthy controls. The drop in ulcerative colitis was more modest. Fungal makeup also differed between bowel disease and healthy controls. A rise in Candida was the most reproducible change. Saccharomyces cerevisiae was often lower. Malassezia was linked to gut inflammation. Fungal changes persisted even in remission.

What it means for patients

The authors said bowel disease goes with a marked change in gut fungi. This was mainly in Crohn's disease. They said these changes may add to immune problems. They said gut fungi may be a source of biomarkers and targets.

Why it is not certain yet

The studies compared groups, so cause is not shown. The authors say the changes may add to disease. The review was not registered in advance.

Source

Gut mycobiome dysbiosis in inflammatory bowel disease: a systematic review and meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.